A Phase 3 interventional study of bupropion XL in Depressive Disorder, Major, sponsored by GlaxoSmithKline. Completed at 16 sites in 6 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2013-09-02.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing bupropion in Depressive Disorder, Major — 1 open to participants now, 3 under way, none of them phase 3. Bupropion · Depressive Disorder, Major.
Among the 37 studies testing bupropion in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 4 that started in 2004, is one of 7 in phase 3, and was the 3rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 37 studies testing bupropion in Depressive Disorder, Major is open now. Recruiting first, the newest first:
Bausch Health Americas, Inc.
Ages 7–17
Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 364 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 74 across the 37 interventional studies. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 37 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
29 studies in Depressive Disorder, Major by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 29 finished, 8 (28%) have results posted.
Among the 29 studies in Depressive Disorder, Major by GlaxoSmithKline, this one is the 13th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2004, is one of 8 in phase 3, and was the 10th registered.
GlaxoSmithKline’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing bupropion in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05273996David SteffensPredictors of Cognitive Outcomes in Geriatric Depression | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies testing bupropion in Depressive Disorder, Major, from their registry updates:
Among GlaxoSmithKline’s 29 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Montgomery-Asberg Depression Rating Scale
Montgomery-Asberg Depression Rating Scale Clinical Global Impression Improvement Scale Clinical Global Impression Severity Scale Hamilton Anxiety Rating Scale
The record gives a start of Jun 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupropion